Provided by Tiger Fintech (Singapore) Pte. Ltd.

Harrow Health Inc

25.55
+0.48001.91%
Pre-market: 25.32-0.2300-0.90%06:39 EDT
Volume:548.54K
Turnover:13.70M
Market Cap:910.96M
PE:-52.11
High:25.58
Open:24.85
Low:24.09
Close:25.07
Loading ...

Harrow Authorizes Nordic Group Unit to sell Generic Version of Maxitrol eye Treatment

MT Newswires Live
·
25 Apr

Nordic Group B.v. Through Its Subsidiary Nordic Pharma, Inc. (U.S.), Announces Launch of Authorized Generic of Maxitrol® (Neomycin and Polymyxin B Sulfates and Dexamethasone Ophthalmic Suspension)

THOMSON REUTERS
·
24 Apr

Nordic Pharma - Partners With Harrow to Launch Generic Maxitrol

THOMSON REUTERS
·
24 Apr

Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic ...

GuruFocus.com
·
22 Apr

BRIEF-Harrow - Klarity-C Patients To Access Vevye For $59 Per Bottle

Reuters
·
10 Apr

Harrow Inc - Klarity-C Patients to Access Vevye for $59 per Bottle

THOMSON REUTERS
·
10 Apr

Harrow Expands VEVYE® Access for All Program to ImprimisRx’s Klarity-C Patients

Business Wire
·
10 Apr

Harrow Is Maintained at Buy by B. Riley Securities

Dow Jones
·
02 Apr

B. Riley Adjusts Price Target on Harrow to $65 From $69, Maintains Buy Rating

MT Newswires Live
·
01 Apr

Harrow Price Target Maintained With a $57.00/Share by HC Wainwright & Co.

Dow Jones
·
31 Mar

Harrow Inc (HROW) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Initiatives

GuruFocus.com
·
30 Mar

Stock Track | Harrow Health Soars 5.13% Pre-Market on Strong Q4 Earnings Beat and Revenue Growth

Stock Track
·
28 Mar

Harrow (HROW) Q4 Earnings and Revenues Top Estimates

Zacks
·
28 Mar

Harrow Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
28 Mar

Harrow Inc Shares up 7.7% at $30.02 After the Bell Following Results

THOMSON REUTERS
·
28 Mar

BRIEF-Harrow Inc Reports Fourth-Quarter & Year-End 2024 Audited Financial Results

Reuters
·
28 Mar

Rpt-Harrow Health Q4 Revenue USD 66.8 Million VS. Ibes Estimate USD 61.8 Million

THOMSON REUTERS
·
28 Mar

Corrected-Harrow Inc: Q4 Core EPS $0.40 (Adds Dropped Word 'Core')

THOMSON REUTERS
·
28 Mar

Rpt-Harrow Health Q4 Core Gross Margin 84%

THOMSON REUTERS
·
28 Mar

Harrow Q4 2024 Adj. EPS $0.40 Beats $0.07 Estimate, Sales $66.800M Beat $61.790M Estimate

Benzinga
·
28 Mar